Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by K. Boughan
Safety and Efficacy of Venetoclax Combined With Rituximab, Ifosfamide, Carboplatin and Etoposide (Vicer) for Treatment of Relapsed Dlbcl: Final Results From the Phase 1trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Safety and Efficacy of Atezolizumab, Obinutuzumab and Venetoclax Combination for Relapsed/Refractory Non-Hodgkin Lymphomas: Results From the Safety-Run of a Lysa Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bet Inhibitor Rg6146, Venetoclax, and Rituximab Is a Highly Active Regimen in Relapsed/Refractory (R/R) Dlbcl: Initial Report of Phase 1b Safety, Biomarker, and Response Data
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Allogeneic Transplantation After a Conditioning Regimen With Ifosfamide, Carboplatin and Etoposide (ICE)
Bone Marrow Transplantation
Transplantation
Hematology
VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
High-Dose Chemotherapy With Carboplatin, Etoposide and Ifosfamide Followed by Autologous Stem Cell Rescue in Patients With Relapsed or Refractory Malignant Lymphomas: A Phase I/Ii Study
Bone Marrow Transplantation
Transplantation
Hematology
Dose Finding Study to Assess Safety, Pk and Efficacy of Fimepinostat (Cudc-907) With Venetoclax or Rituximab Plus Bendamustine in Patients With Relapsed/Refractory Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Addition of Lenalidomide to Rituximab, Ifosfamide, Carboplatin, Etoposide (RICER) in First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
British Journal of Haematology
Hematology
Final Results of a Phase 1b Study of the Safety and Efficacy of the PI3Kδ Inhibitor Acalisib (GS-9820) in Relapsed/Refractory Lymphoid Malignancies
Blood Cancer Journal
Oncology
Hematology
PHASE 1B STUDY OF ViPOR (VENETOCLAX, IBRUTINIB, PREDNISONE, OBINUTUZUMAB, LENALIDOMIDE) IN RELAPSED/REFRACTORY B-Cell LYMPHOMA: SAFETY, EFFICACY AND MOLECULAR ANALYSIS
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
